Trial Profile
An Open-Label Study to Explore the Safety, Efficacy and Pharmacokinetics of TMC207 in Japanese Patients With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Bedaquiline (Primary) ; Antituberculars
- Indications Pulmonary tuberculosis
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 27 Dec 2018 Status changed from active, no longer recruiting to completed.
- 08 May 2018 Status changed from recruiting to active, no longer recruiting.
- 22 Dec 2016 Planned End Date changed from 1 Nov 2018 to 1 Sep 2020.